Rapidly dissolving microneedle patch of amphotericin B for intracorneal fungal infections

Drug Deliv Transl Res. 2022 Apr;12(4):931-943. doi: 10.1007/s13346-021-01032-2. Epub 2021 Jul 23.

Abstract

Chronic fungal infection of the cornea could lead to blindness if not treated properly. Topical amphotericin B (AMP-B) is considered the first treatment of choice for ocular fungal infection. However, factors related to its poor solubility and penetration through intact cornea lead to poor bioavailability. Microneedles (MNs) are emerging as a minimally invasive method to enhance ocular drug delivery. This study aims to investigate the potential use of biodegradable poly(vinylpyrrolidone) (PVP) and hyaluronic acid (HA)-based rapidly dissolving MNs for delivery of AMP-B to treat fungal infection. The data obtained illustrates PVP/HA MN arrays' reproducibility, good mechanical strength, and faster dissolution with 100% drug recovery. Multiphoton microscopic results revealed that MNs successfully penetrate the corneal tissue and enhance AMP-B permeation through corneal layers. Furthermore, PVP/HA MN arrays showed high solubility. Both PVP and HA successfully decreased AMP-B cytotoxicity when compared to free drug. More interestingly, the biocompatible MN formulations preserved the antifungal activity of AMP-B, as demonstrated by significant inhibition of fungal growth. Therefore, this study shows the feasibility of ocular delivery of the poorly soluble AMP-B using a fast-dissolving MN patch.

Keywords: Amphotericin B; Biocompatibility; Hyaluronic acid; Intracorneal; Microneedles; Poly (vinylpyrrolidone).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous
  • Amphotericin B*
  • Drug Delivery Systems / methods
  • Eye Infections, Fungal* / drug therapy
  • Humans
  • Hyaluronic Acid / therapeutic use
  • Needles
  • Reproducibility of Results

Substances

  • Amphotericin B
  • Hyaluronic Acid